Breast cancer - HealthQuill

Novartis AG, the world's fourth-largest pharmaceutical company by revenue, announced its Kisqali drug reduced breast cancer recurrence when diagnosed at an early stage and has stopped its ongoing trial.

New study finds some healthy breast cells may harbor cancer cells

Bharti Jayshankar November 30, 2024: A study done by the University of Texas MD Anderson Cancer Center revealed that some breast cells in healthy.

by HealthQuill
November 30, 2024
0 Comments

AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of breast cancer in the US.

Drugs Health Pharma

AstraZeneca, Daiichi’s Enhertu drug gets FDA’s priority review in US

AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.

by HealthQuill
October 1, 2024
0 Comments

Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an upfront payment of $850 million.

Drugs Health Pharma

Roche arm to buy breast cancer portfolio from Regor for $850 million

Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an.

by HealthQuill
September 30, 2024
0 Comments

Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of an absence of cancer in treated patients.

Drugs Health Pharma

Henlius, Organon trial drug meets goal of an absence of breast cancer

Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of.

by HealthQuill
September 30, 2024
0 Comments

British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an end-stage trial, according to a joint statement.

Drugs Health Pharma

AstraZeneca-Daiichi Sankyo’s breast cancer drug fails in late-stage trial

British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an.

by HealthQuill
September 24, 2024
2 Comments

Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in people born in 1990 than in 1995, a study reveals.

Drugs Health Pharma

GenX faces a higher risk of 17 cancer types than older generation

Seventeen types of cancer are common in US millennials and the incidence rate for some forms is two to three times higher in.

by HealthQuill
August 4, 2024
0 Comments

Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered at a “fair price.”

Drugs Health Pharma

UK watchdog blocks AstraZeneca, Daiichi’s breast cancer drug

Daiichi Sankyo and AstraZeneca’s breast cancer treatment ran into opposition from the UK’s healthcare spending watchdog, which wants Enhertu drug to be offered.

by HealthQuill
July 29, 2024
0 Comments

AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.

Drugs Health Pharma

AstraZeneca’s trial breast cancer drug fails to meet primary goals

AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.

by HealthQuill
June 18, 2024
0 Comments

AstraZeneca, Daiichi’s breast cancer drug trial results show improvement in progression-free survival

Drugs Health Pharma

AstraZeneca, Daiichi’s breast cancer drug trials show rise in survival

HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.